Dr. Reddy's, Aurobindo Face USFDA 483s; Biocon Secures Aflibercept Deal

• Dr Reddy's Laboratories received five observations in a USFDA Form 483 after an inspection at its Srikakulam facility.
• Aurobindo Pharma's API manufacturing facility in Telangana received three procedural observations in a USFDA Form 483.
• Biocon Biologics signed a settlement and licensing agreement with Regeneron and Bayer for global commercialization of its biosimilar Aflibercept (Yesafili).
• The agreement allows Biocon Biologics to launch Yesafili in the UK in January 2026 and other settled countries by March 2026.
• Shares of Dr Reddy's, Aurobindo Pharma, and Biocon all saw declines on Monday following the news.

Why It Matters: Regulatory actions and strategic deals shape pharma stock performance.